Shares of Celcuity (NASDAQ:CELC) surged as much as 75% in premarket trading on Monday after the biotech firm announced it had completed patient recruitment for its pivotal Phase 3 breast cancer trial targeting tumors with the PIK3CA mutation.
The late-stage study is evaluating a novel therapy that includes the drug gedatolisib, with the company also unveiling encouraging clinical data from patients carrying the mutation.
The sharp rally reflects investor optimism over this major milestone, which marks a significant step forward in the advancement of Celcuity’s breast cancer treatment program.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.